Akari Initiates GMP Manufacturing for AKTX-101 Antibody-Drug Conjugate
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- GMP Manufacturing Initiation: Akari Therapeutics announced the initiation of GMP manufacturing for its lead antibody-drug conjugate, AKTX-101, marking a pivotal step toward its planned Phase 1 clinical trial expected to start in late 2026 or early 2027, reflecting the company's confidence in its scientific approach.
- Innovative Drug Mechanism: AKTX-101 utilizes a proprietary PH1 payload designed to target the Trop2 receptor on cancer cells, combining direct cytotoxicity with immune activation, which could potentially offer superior therapeutic outcomes compared to existing options.
- Strategic Partnership: Akari has partnered exclusively with WuXi XDC, a global leader in ADC development and manufacturing, leveraging their integrated platform to accelerate the production of GMP-grade material, thereby enhancing the company's competitive positioning in the market.
- Upcoming Milestones: The company plans to complete GMP manufacturing to support IND submission within the next 12 months and continue validating the PH1 payload across undisclosed targets in its pipeline, which, if successful, could redefine the therapeutic landscape for antibody-drug conjugates.
AKTX
$0.2453+Infinity%1D
Analyst Views on AKTX
Wall Street analysts forecast AKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTX is 4.53 USD with a low forecast of 1.60 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.264
Low
1.60
Averages
4.53
High
7.00
Current: 0.264
Low
1.60
Averages
4.53
High
7.00
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
